Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

Figure 4

ASAS40. Percentage of patients who achieved an ASAS40. P-value of adalimumab treated patients versus placebo is outlined based on an intention-to-treat analysis (χ2-test). One patient in each group discontinued prematurely before week 4. The data were included in a last observation carried forward modus. At week 12, all patients remaining patients switched to open label adalimumab.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us